"RX-3117 is effective in at least 50 cancer cell lines in humans, affording it broad potential. Although management has not yet revealed which cancer indication will be pursued in trials scheduled for later this year, the above-mentioned lines include lung, kidney, colon and pancreas, representing combined worldwide markets of over $30 billion. RX-3117 has also overcome resistance to certain chemotherapy drugs, enhancing its value as a companion treatment.
Not long ago, the license to RX-3117 was returned to Rexahn when its alliance with Teva Pharmaceutical Industries Limited (TEVA) unraveled after Teva's readjustment of its pipeline focus, as previously reported. This could eventually work in Rexahn's favor as new, better suited partners show interest.
RX-3117 should prove to be a valuable pipeline addition to Rexahn's key drug, Archexin, an Akt-1 inhibitor showing strong signs of cancer-fighting ability now solidly in Phase II trials for pancreatic disease, and the recipient of the FDA's prized Orphan Drug status for up to five different indications. Pancreatic cancer is a stubborn disease to treat; Amgen, Inc. (AMGN) was not successful, nor was Merck & Co. (MRK), leaving Rexahn in the lead.
Rexahn faces the same risks of any innovative biotech firm -- clinical and regulatory hurdles, capital funding requirements, and competition from larger, better-financed drug firms. The company NOW has 20 million in cash due to a recent offering and uses operating funds conservatively. Earnings per share loss, reflective of its burn rate, widened only slightly in the three months ended June 30th, from ($0.01) to ($0.03).
This is a company with huge potential, trading at an undeserved market capitalization of $67.8 million, set to introduce new cancer compounds directed toward billion dollar industries, with one of its lead drugs based on oral administration where the safety of human biochemistry effectively removes a regulatory roadblock."
Hmmm people will know when RNN delivers no need to spread the word....as they go with the next stage of clinical trials and postive results this will move higher ......coming to risk they failed with Serdaxin which could have brought them huge revenue that doesn't mean they will fail with the current ones yes there is risk as this is penny and going alone without any partner...Teva leaving them but one postive is it gives them huge oppurtunity if they can succeed with the new drug could be Teva's big loss ...only time will tell....JMHO do ur own dd